Chemomab Therapeutics Ltd. CMMB
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a GI/hepatology drug developer. Its lead program, nebokitug, is in Phase 2 for primary sclerosing cholangitis (PSC). Its next catalyst on record is Product (CCL24 program): Parent must initiate Phase II trial within twelve months following FDA acceptance of an IND for the Product. (Q4 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Product (CCL24 program) — Parent must initiate Phase II trial within twelve months following FDA acceptance of an IND for the Product. (Q4 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| nebokitug | primary sclerosing cholangitis (Phase 2 complete; single pivotal Phase 3 design agreed with FDA) | antibody | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.